摘要
世界范围内,组织器官纤维化是许多疾病致残、致死的主要原因,目前尚没有能够阻止、逆转纤维化病变的药物,因此寻找和研发抗纤维化药物具有重大意义。组织器官纤维化病变是与细胞外基质过度沉积相关的非生理性瘢痕形成过程,可导致组织器官功能障碍,所有器官的纤维化病变具有相似的组织学异常改变。近年来,大量研究表明黄芩苷和黄芩素具有抑制多组织器官纤维化的作用,该文就黄芩苷和黄芩素在抗不同器官纤维化的作用和作用机制进行了综述。黄芩苷及其苷元黄芩素结构和药理作用相似,在体内存在广泛的生物转化作用,研究表明,黄芩苷和黄芩素能够通过抑制促纤维因子表达、抑制纤维化相信号通路、抗炎、抗氧化等多种机制抑制不同组织器官纤维化的发生和发展,是一种具有开发潜力的多组织器官抗纤维化药物。但目前关于黄芩苷和黄芩素抗纤维化研究也存在一些问题,作为非常有希望的潜在抗多器官组织纤维化药物,黄芩苷和黄芩素的抗纤维化研究有待于进一步加强。
Tissue and organ fibrosis is the major cause for disability and death related to a variety of diseases worldwide. As specific therapies to halt, or even to reverse the existing tissue fibrosis are not yet available, it is of great significance to find new anti-fibrosis therapeutic agents. Tissue and organ fibrosis is a nonphysiological scarring process, associated with excessive deposition of extracellular matrix, and leads to impairment of organ function. Fibrotic lesions of all organs show similar histological abnormalities. In recent years, plenty of studies showed that Baicalin and baicalein had anti-fibrosis effects in different tissues or organs. In this paper, the effects and mechanisms of baicalin and baicalein on different organ fibrosis were reviewed. Baicalin and its aglycone baicalein had similarity in structural and pharmacological characteristics, with broad biotransformation effect within the body. The research suggested that baicalin and baicalein can suppress different tissue and organ fibrosis occurrence and development via various mechanisms, including down-regulating expression of promote-fibrosis cytokines, inhibiting pro-fibrogenic signaling pathways, anti-inflammatory and anti-oxidant effects. Though baicalin and baicalein are promising anti-fibrosis agents, there is still a long way to go before being approved as specific anti-fibrotic drugs.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2017年第7期1271-1276,共6页
China Journal of Chinese Materia Medica
基金
国家"重大新药创制"科技重大专项(2014ZX09509001-001)
山东省高等学校科技计划项目(J14LK09)
山东省高校中医药抗病毒协同创新项目(XTCX2014B-01)
